Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Sofinnova Partners Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Twitter
Linkedin
Crunchbase
Metrics
2,015,644Website Global Rank
8,743Website Monthly Traffic
Twitter Followers
Description
Sofinnova Partners is a venture capital firm that invests in the life sciences sector, from seed to later-stage. The firm manages over €2 billion of assets dedicated to life science investing and actively partners with ambitious entrepreneurs as a lead or cornerstone investor to develop transformative innovations that have the potential to positively impact its collective future. It invests in start-ups, early-stage companies, corporate spin-offs, and occasionally turnaround situations with a focus on Life Sciences (Biopharmaceuticals / Biotech, Medical Devices, Industrial Biotechnology). Sofinnova Partners proactively sources deals, takes a lead role, is most often the first institutional investor in Round A financings, and leads its portfolio companies until exit. They sit on the boards of their portfolio companies and play an active role from the formation phase alongside entrepreneurs. It was headquartered in Paris, Ile-de-France in 1972.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 7/2020 | Enthera | Series A | 0 |
| 3/2016 | CelluComp | Venture Round | 5.3M |
| 1/2006 | Blyk | Series A | 35.4M |
| 3/2018 | SafeHeal | Series A | 7.4M |
| 7/2020 | MISSION Therapeutics | Venture Round | 15M |
| 11/2021 | Synthace | Series C | 35M |
| 1/2007 | Stentys | Seed Round | - |
| 1/2010 | BioAmber | Series A | 0 |
| 10/2022 | Mablink Bioscience | Series A | 30.1M |
| 9/2013 | Synthace | Seed Round | 2.1M |
| 7/2021 | protera | Series A | 0 |
| 5/2004 | Addex Therapeutics | Series B | 0 |
| 3/2009 | Neosens | Series B | 5.3M |
| 2/2008 | Neosens | Venture Round | 3.7M |
| 3/2007 | MXP4 | Series A | 6.5M |
| 5/2009 | MXP4 | Series B | 2.7M |
| 1/2004 | Infra Worlds | Series A | 1.7M |
| 1/2023 | Amolyt Pharma | Series C | 0 |
| 5/2023 | BrightHeart | Seed Round | 2.1M |
| 2/2019 | GenSight Biologics | Post-IPO Equity | 9.1M |
| 9/2022 | Abivax | Post-IPO Equity | 0 |
| 11/2013 | Pixium Vision | Series A | 20.3M |
| 4/2020 | RefleXion Medical | Series D | 0 |
| 1/2008 | CrestaTech | Series A | 5M |
| 7/2009 | EOS (Ethical Oncology Science) | Series A | 17M |
| 1/2005 | CrestaTech | Seed Round | 1.5M |
| 10/2011 | Hookipa Pharma | Series A | 9.6M |
| 1/2013 | ProQR Therapeutics | Seed Round | - |
| 1/2009 | DBV Technologies | Series B | 7.8M |
| 1/2006 | DBV Technologies | Venture Round | 15.1M |
| 3/2018 | Micropep Technologies | Series A | 5M |
| 4/2006 | Endoart | Series C | 0 |
| 2/2003 | Avaki | Series A | 4.2M |
| 3/2008 | Laszlo Systems | Series C | 14.6M |
| 4/2018 | Crescendo Biologics | Series B | 0 |
| 4/2016 | MedDay | Series B | 0 |
| 10/2000 | Ingenium Pharmaceuticals AG | Series B | 44M |
| 12/2016 | Hookipa Pharma | Series B | 10.7M |
| 11/2011 | NuCana BioMed | Series A | 10.5M |
| 7/2019 | AblaCare | Series A | 11.2M |
| 2/2017 | Zyl | Venture Round | - |
| 12/2013 | Crescendo Biologics | Series A | 28.5M |
| 12/2021 | DMC Biotechnologies | Series B | 0 |
| 12/2019 | DMC Biotechnologies | Series A | 0 |
| 12/2022 | EnginZyme | Series B | 22.3M |
| 5/2022 | GFBiochemicals | Series A | 0 |
| 12/2018 | Shockwave Medical | Series D | 0 |
| 3/2017 | Biotalys | Series B | 0 |
| 12/2007 | Fovea Pharmaceuticals | Series B | 30M |
| 7/2007 | Inside Secure | Series B | 0 |
| 1/2002 | Innate Pharma | Series B | 17.8M |
| 3/2000 | Innate Pharma | Series A | 4.4M |
| 3/2023 | Noema Pharma | Series B | 0 |
| 3/2023 | Mediar Therapeutics | Series A | 0 |
| 12/2013 | Green Biologics | Series B | 0 |
| 4/2004 | Ablynx | Series B | 30M |
| 11/2003 | Esmertec AG | Series C | 0 |
| 7/2006 | Accent | Venture Round | 13.3M |
| 5/2019 | DNA Script | Series B | 38.5M |
| 1/2009 | Revolt Technology | Series B | 13.1M |
| 2/2008 | Ocera Therapeutics | Series C | 0 |
| 10/2006 | Domain Therapeutics | Series C | 10.4M |
| 6/2021 | Borea Therapeutics | Seed Round | - |
| 6/2005 | Revolt Technology | Series A | 8.5M |
| 5/2015 | Twenga | Series A | 11M |
| 10/1998 | BoostWorks | Series A | 3M |
| 2/2002 | Tak Imaging | Series B | 9.5M |
| 12/2012 | Flexion Therapeutics | Series B | 20M |
| 4/2008 | Qosmos | Series C | 10.8M |
| 11/2021 | GlycoEra | Series A | 0 |
| 1/2005 | VoluBill | Series C | 0 |
| 1/2004 | Intransa | Series C | 8M |
| 10/2004 | Sensitive Object | Series A | 2.5M |
| 5/2010 | Crocus Technology | Series C | 0 |
| 7/2021 | Artios Pharma | Series C | 0 |
| 9/2019 | Inotrem | Series B | 43.1M |
| 4/2018 | LimFlow SA | Series C | 33.4M |
| 9/2007 | Purple Labs | Series A | 12.7M |
| 8/2022 | F2G | Private Equity Round | 0 |
| 7/2005 | Filao | Venture Round | 0 |
| 6/2019 | Comet Therapeutics | Series A | 28.5M |
| 7/2007 | GlycoVaxyn | Series A | 9.5M |
| 4/2002 | Esmertec AG | Venture Round | 8.8M |
| 7/2021 | protera | Series A | 0 |
| 4/2013 | Aledia | Series A | 12.8M |
| 11/2002 | PhyFlex Networks | Series B | 0 |
| 1/2019 | HighLife | Series B | 36M |
| 2/2002 | Domain Therapeutics | Series A | 2.6M |
| 7/2021 | Micropep Technologies | Series A | 10.1M |
| 6/2022 | Micropep Technologies | Series A | 0 |
| 7/2019 | Biotalys | Series C | 0 |
| 1/2007 | Movetis | Series A | 63.8M |
| 10/2010 | ASSIA | Series D | 20.8M |
| 6/2010 | QuesCom | Venture Round | 0 |
| 1/2003 | Intransa | Series B | 6M |
| 7/2020 | Pixium Vision | Post-IPO Equity | 8.3M |
| 9/2017 | Synthace | Series A | 9.9M |
| 7/2002 | Addex Therapeutics | Series A | 9.9M |
| 10/2018 | Sitryx Therapeutics | Series A | 30M |
| 4/2020 | Pi-Cardia | Venture Round | 27M |
| 9/2017 | DNA Script | Series A | 13.2M |
| 11/2021 | Nitrase Therapeutics | Series A | 0 |
| 5/2020 | HotSpot Therapeutics | Series B | 65M |
| 4/2005 | Tak Imaging | Series C | 10M |
| 3/2020 | Redx Pharma | Post-IPO Equity | 33.6M |
| 9/2002 | Ablynx | Series A | 4.9M |
| 3/2004 | UPEK | Series A | 20M |
| 7/1999 | BoostWorks | Series B | 7M |
| 11/2005 | Fovea Pharmaceuticals | Series A | 24.2M |
| 6/2020 | Protera | Series A | 5.6M |
| 1/2004 | Tak Imaging | Series C | 16.3M |
| 10/2009 | Flexion Therapeutics | Series A | 33M |
| 7/2022 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series D | 0 |
| 7/2019 | Comet Biorefining | Venture Round | - |
| 2/2013 | MetGen | Venture Round | 2.9M |
| 1/2015 | Green Biologics | Equity | 42M |
| 3/2008 | Mobile Digital Media | Venture Round | 0 |
| 8/2004 | Intransa | Series D | 24M |
| 4/2018 | Inventiva Pharma | Post-IPO Equity | 44.4M |
| 11/2006 | Abionyx Pharma | Series B | 53.5M |
| 1/2005 | Biolipox | Series C | 41M |
| 12/2007 | Streamezzo | Series C | 22M |
| 2/2002 | Intransa | Venture Round | 10M |
| 5/2010 | Noxxon Pharma | Series D | 40.7M |
| 2/2015 | Synthace | Venture Round | 3.4M |
| 11/2006 | CoreValve | Venture Round | 20M |
| 2/2016 | MISSION Therapeutics | Series C | 86.5M |
| 10/2009 | Crescendo Biologics | Seed Round | 0 |
| 3/2014 | Inotrem | Series A | 25.1M |
| 5/2004 | Domain Therapeutics | Series B | 19.1M |
| 5/2007 | Noxxon Pharma | Series C | 50.2M |
| 1/2018 | Aledia | Series C | 0 |
| 7/2006 | GlycoVaxyn | Seed Round | - |
| 11/2018 | InCarda Therapeutics | Series B | 42M |
| 5/2014 | Avantium | Series G | 0 |
| 4/2018 | Erydel | Series B | 32.4M |
| 4/2014 | RefleXion Medical | Series A | 11.6M |
| 9/2020 | POLYNEURON | Series A | 15.4M |
| 11/2014 | myTomorrows | Venture Round | 5.6M |
| 10/2017 | HighLife | Series A | 14.3M |
| 10/2020 | GenSight Biologics | Post-IPO Equity | 0 |
| 7/2018 | HotSpot Therapeutics | Series A | 45M |
| 2/2012 | BioAmber | Series C | 0 |
| 4/2014 | Crescendo Biologics | Series A | 3.3M |
| 10/2011 | Creabilis | Series B | 20M |
| 5/2018 | Biosyntia | Series A | 4.7M |
| 3/2009 | GlycoVaxyn | Series B | 21.4M |
| 4/2006 | Varioptic | Series C | 0 |
| 11/2019 | TISSIUM | Series B | 43.2M |
| 6/2018 | Castle Biosciences | Venture Round | 0 |
| 6/2009 | blueKiwi software | Series B | 0 |
| 6/2015 | Aledia | Series B | 0 |
| 7/2019 | Microphyt | Venture Round | 31.9M |
| 4/2015 | ReCor Medical | Series D | 15M |
| 4/2020 | Nitrase Therapeutics | Series A | 38M |
| 1/2008 | TAK imaging | Series C | 16.2M |
| 9/2002 | EnvoyWorldWide | Series C | 4.5M |
| 6/2016 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series B | 33M |
| 1/2003 | Biolipox | Series B | 21M |
| 9/2006 | Addex Therapeutics | Series C | 0 |
| 12/2021 | EndoRon Medical | Seed Round | 5M |
| 2/2019 | AFYREN | Venture Round | 23.8M |
| 3/2008 | Stentys | Series A | 18M |
| 6/2018 | NodThera | Series A | 40M |
| 2/2018 | Mainstay Medical | Post-IPO Equity | 37.5M |
| 2/2021 | Mainstay Medical | Private Equity Round | 0 |
| 1/2007 | blueKiwi software | Series A | 5.3M |
| 7/2021 | Muna Therapeutics | Series A | 0 |
| 10/2021 | Leucid Bio | Series A | 15.9M |
| 7/2022 | Biosyntia | Series B | 11.7M |
| 9/2004 | Innate Pharma | Series C | 0 |
| 1/2011 | DBV Technologies | Series C | 25.5M |
| 10/2003 | Cotherix | Series C | 55M |
| 4/2014 | NuCana | Series B | 0 |
| 5/2019 | CinCor Pharma | Series A | 50M |
| 3/2004 | Varioptic | Series B | 12.2M |
| 5/2009 | Streamezzo | Series D | 5.5M |
| 2/2016 | Corvidia | Series A | 26M |
| 4/2016 | RefleXion Medical | Series B | 52M |
| 4/2018 | RefleXion Medical | Series C | 100M |
| 4/2006 | Streamezzo | Series B | 0 |
| 1/2007 | Sequoia Pharmaceuticals | Series C | 35M |
| 11/2016 | Shockwave Medical | Series C | 45M |
| 4/2018 | EnobraQ | Seed Round | 3.6M |
| 7/2010 | Abionyx Pharma | Series C | 0 |
| 6/2021 | Mnemo Therapeutics | Series A | 90M |
| 3/2017 | Comet Biorefining | Venture Round | - |
| 7/2021 | Comet Biorefining | Series C | 0 |
| 10/2016 | MD Start | Venture Round | 0 |
| 5/2015 | Shockwave Medical | Series B | 40M |
| 11/2013 | Hookipa Pharma | Series B | 27M |
| 6/2013 | MetGen | Series A | - |
| 6/2021 | Alia Therapeutics | Seed Round | - |
| 6/2016 | DNA Script | Seed Round | 2.8M |
| 3/2007 | CoreValve | Series C | 33M |
| 8/2005 | Abionyx Pharma | Series A | 30.5M |
| 5/2019 | Twentyeight-Seven Therapeutics | Series A | 15M |
| 12/2017 | Hookipa Pharma | Series C | 0 |
| 11/2020 | Catamaran Bio | Series A | 0 |
| 11/2003 | Saegis Pharmaceuticals | Series B | 30M |
| 1/2008 | Inside Secure | Series C | 0 |
| 12/2020 | Noema Pharma | Series A | 60M |
| 3/2023 | BioCorteX | Seed Round | 0 |
| 2/2006 | Lectus Therapeutics | Series A | 14.3M |
| 6/2020 | NodThera | Series B | 55M |
| 3/2011 | Omthera Pharmaceuticals | Series B | 33.9M |
| 4/2005 | Laszlo Systems | Series B | 6.3M |
| 9/2007 | VoluBill | Series D | 0 |
| 1/2017 | myTomorrows | Venture Round | 10.6M |
| 9/2016 | IOmx Therapeutics | Series A | 44.6M |
| 10/2021 | IOmx Therapeutics | Series B | 0 |
| 4/2018 | Corvidia | Series B | 60M |
| 3/2017 | Breath Therapeutics | Series A | 45.9M |
| 5/2020 | CorVent Medical | Seed Round | 0 |
| 2/2023 | Abivax | Post-IPO Equity | 0 |
| 2/2010 | Odoo | Series A | 4.1M |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 11/2021 | HotSpot Therapeutics | Series C | 0 |
| 10/2021 | CinCor Pharma | Series B | 0 |
| 11/2013 | MISSION Therapeutics | Series B | 32.2M |
| 10/2021 | Mozart Therapeutics | Series A | 0 |
| 8/2011 | MISSION Therapeutics | Series A | 6M |
| 1/2021 | Corwave | Series C | 43.2M |
| 4/2020 | Pyrowave | Series B | - |
| 11/2013 | CelluComp | Seed Round | 3.9M |
| 7/2018 | Enthera | Seed Round | 4.7M |
| 6/2021 | AAVantgarde Bio | Seed Round | - |
| 9/2006 | Qosmos | Series B | 4.1M |
| 1/2014 | Shockwave Medical | Series A | 12.5M |
| 6/2022 | Moon Surgical | Series A | 31.3M |
| 2/2022 | Elicit Plant | Series A | 18.3M |
| 1/2002 | EnvoyWorldWide | Series B | 8M |
| 4/2013 | Auris Medical | Series C | 51M |
| 2/2015 | Comet Biorefining | Venture Round | - |
| 3/2017 | HotSpot Therapeutics | Seed Round | - |
| 11/2020 | Myricx Pharma | Seed Round | 5.9M |
| 1/2003 | Varioptic | Series A | 2.1M |
| 2/2013 | Entourage Medical Technologies | Venture Round | 3.3M |
| 9/2019 | Inventiva Pharma | Post-IPO Equity | 681.2k |
| 3/2019 | POLYNEURON | Series A | 22.6M |
| 12/2009 | Sensitive Object | Series B | 6M |
| 10/2021 | Sphere Fluidics | Venture Round | 41.4M |
| 11/2015 | ObsEva | Series B | 58.9M |
| 6/2008 | Creabilis | Series A | 31.4M |
| 11/2011 | NuCana | Series A | 0 |
| 9/2015 | Asceneuron | Series A | 30.8M |
| 4/2020 | Genespire | Series A | 17.4M |
| 4/2005 | TAK imaging | Series C | 10M |
| 11/2022 | Microphyt | Series B | 0 |
| 9/2006 | Oxxius | Series B | 10M |
| 6/2005 | Endotis | Series A | 4.9M |
| 5/2005 | Sefas Innovation | Venture Round | 3.8M |
| 5/2014 | Odoo | Series B | 10M |
| 9/2016 | Delinia | Series A | 35M |
| 1/2022 | SafeHeal | Venture Round | 0 |
| 10/2006 | Wyplay | Series A | 5.1M |
| 9/2004 | Oxxius | Series A | 2.9M |
| 2/2020 | Inventiva Pharma | Post-IPO Equity | 16.4M |
| 6/2007 | PregLem | Series A | 26M |
| 3/2016 | TISSIUM | Series A | 25.5M |
| 8/2008 | mydeco | Series A | 14.5M |
| 7/2007 | Diatos | Series D | 12.8M |
| 6/2019 | AFYX Therapeutics | Debt Financing | 13M |
| 7/2010 | Mainstay Medical | Series A | 6.1M |
| 10/2018 | Inspirna, Inc.(formerly Rgenix, Inc.) | Series C | 40M |
| 4/2020 | Epsilen Bio | Seed Round | - |
| 11/2016 | Corwave | Series B | 17.1M |
| 11/2021 | Home Biosciences | Seed | 15M |
| 5/2020 | PinCell s.r.l. | Seed Round | 1.6M |
| 12/2007 | PregLem | Series B | 32.2M |
| 4/2020 | EnginZyme | Series A | 6.9M |
| 4/2022 | Prometheus Materials | Series A | 8M |
| 8/2021 | TISSIUM | Series C | 59.1M |
| 1/2016 | ENYO Pharma | Series A | 23.9M |
| 4/2013 | MedDay | Series A | 10.5M |
| 7/2019 | Abivax | Post-IPO Equity | 13.5M |
| 3/2010 | Omthera Pharmaceuticals | Series A | 6.5M |
| 10/2002 | Cobion | Venture Round | 5.9M |
| 8/2006 | Ablynx | Series C | 50M |
| 12/2021 | Meiogenix | Series A | 12.4M |
| 8/2000 | BioSpace | Series B | 10M |
| 4/2022 | LimFlow SA | Series D | 0 |
| 12/2019 | GenSight Biologics | Post-IPO Debt | 16.6M |
| 3/2008 | Filao | Venture Round | 0 |
| 9/2010 | Bee Ware | Series B | 5.6M |
| 5/2005 | Bee Ware | Series A | 3.8M |
| 12/2007 | Ascendis Pharma | Series A | 25.7M |
| 4/2014 | ProQR Therapeutics | Series A | 57.9M |
| 3/2005 | Filao | Venture Round | 4.6M |
| 3/2005 | Sequoia Pharmaceuticals | Series B | 22M |
| 5/2023 | BrightHeart | Seed Round | 0 |
| 5/2023 | TISSIUM | Series D | 0 |
| 5/2023 | Moon Surgical | Series B | 0 |
| 5/2023 | Werewool | Seed Round | 0 |
| 4/2023 | Alia Therapeutics | Seed Round | 0 |
| 3/2023 | BioCorteX | Seed Round | 0 |
| 3/2023 | deepc | Series A | 0 |
| 3/2023 | Kiro | Series A | 0 |
| 3/2023 | Mediar Therapeutics | Series A | 0 |
| 3/2023 | Noema Pharma | Series B | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
